Giyaan Pharma Private Limited - Due diligence report

A 360° intelligence report on Giyaanpharma: trust score, financial health, credit view, compliance, directors, growth and distress signals -…

1992-12-14 Serilingampally, Telangana Active Unlisted Active Compliant
Share
GP Giyaan Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Giyaanpharma — 360° Intelligence Report

Generated from MCA filings & public records
74/100
Trust Score
Moderate

Giyaanpharma is assessed as Moderate with a Trust Score of 74/100. Giyaanpharma is an active private limited indian non-government company incorporated in 1992, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Giyaan Pharma Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
74/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
70/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • Profitable - internal accruals available.

Charges position: 1 open (27.50 cr) · 7 satisfied (36.32 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others5 48.0 cr
Tamilnadu Mercantile Bank Limited1 48.0 cr
Tamilnad Mercantile Bank Limited2 48.0 cr
Compliance Score: 70/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 auditor resignation(s) filed - latest: Reddy A V & Co., on 2017-07-17.
  • Delayed payments to MSME suppliers disclosed (40 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
PUNUGOTI SASIDHAR REDDY 01234567 Director 01/04/2018 6 yrs Approved
PRASADA REDDY KAMBHAM 01234567 Director 01/04/2018 6 yrs Approved
SPOORTHI KAMBAM 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: PUNUGOTI SASIDHAR REDDY (Whole-time director) · PRASADA REDDY KAMBHAM (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 70
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 33+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Negative net worth.
1 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 8.46 Lakh.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 27.50 cr already registered.
  • Compliance record supports lending.
Investor view68/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
27 Sep 2024
Last AGM held
Annual general meeting
14 Jun 2024
Charge satisfied
Others
31 Mar 2024
Latest balance sheet
Filed with ROC
27 Sep 2023
Charge satisfied
Others
19 Jul 2023
Charge created
Others - 27.50 cr
13 Jul 2020
Charge created
Others - 1.95 cr
16 Jul 2019
Securities allotted
1200000 Equity Shares - 1.20 cr raised
17 Jun 2019
Director ceased
PUNUGOTI SASIDHAR REDDY
Director ceased
PRASADA REDDY KAMBHAM
13 Jul 2018
Charge created
Others - 10.92 cr
09 Nov 2017
Charge satisfied
Tamilnad Mercantile Bank Limited
Charge satisfied
Others
Charge satisfied
Tamilnadu Mercantile Bank Limited
06 Nov 2017
Charge created
Others - 19.10 cr
30 Oct 2017
Securities allotted
1231500 Equity Shares - 1.23 cr raised
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Aavishkar U24100TG2013PTC089852 Kothur, Telangana, India
Ark Golden U24229GJ2003PTC071068 Vadodara, Gujarat, India
Ultra Laboratories Private Limited U24231KA2006PTC038442 Bangalore, Karnataka, India
Pro-Pharma Care U85100UR2012PTC000458 Roorkee, Uttarakhand, India
Swiss Pharma U24231GJ1987PTC009343 Ahmedabad, Gujarat, India
Acechemie Zynk Energy Limited U24232GJ2015PLC085471 Amod, Gujarat, India
Mmc Health Care Limited U93090TN1996PLC034651 Chennai, Tamil Nadu, India
Fenasia Limited U65993WB1997PLC082448 Bhadreshwar, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Giyaanpharma before audits and certifications: compliance score 70/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Giyaanpharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 75/100, margin trends, ownership structure and peer set for Giyaanpharma - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 74/100, distress signals and MSME payment-delay disclosures - know whether Giyaanpharma pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Giyaanpharma - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Giyaanpharma an active company?

Giyaanpharma has MCA status “Active” with a compliance score of 70/100 (Moderate).

Is Giyaanpharma financially healthy?

Giyaanpharma has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.

Should I do business with Giyaanpharma?

Its overall Trust Score is 74/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Giyaanpharma?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Giyaanpharma have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 7 earlier charge(s) stand satisfied.

Is Giyaanpharma up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 70/100 (Moderate).

Is it risky to lend to Giyaanpharma?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.